IDEXX Q2 2020 Earnings Report
Key Takeaways
IDEXX Laboratories reported a 3% increase in revenue, reaching $638 million for the second quarter of 2020. This growth was primarily driven by a 7% increase in Companion Animal Group (CAG) Diagnostics recurring revenue. The company's EPS was $1.72, a 20% increase, reflecting revenue growth and cost control benefits.
Reported revenue growth of 3% driven by Companion Animal Group Diagnostics recurring revenue growth of 7%.
Revenue results supported by global 'V-shaped' recovery in the pet healthcare market.
Delivered EPS of $1.72, representing 20% growth, reflecting solid revenue gains and benefits from proactive cost controls.
Overall growth benefited by approximately 1% from revenues associated with OPTI Medical Systems COVID-19 human PCR testing.
IDEXX
IDEXX
IDEXX Revenue by Segment
IDEXX Revenue by Geographic Location
Forward Guidance
The Company is maintaining suspension of full-year 2020 guidance due to the unpredictability of potential future impacts from the COVID-19 pandemic.
Revenue & Expenses
Visualization of income flow from segment revenue to net income